Group 1 - Company Genscript Biotech (stock code: 1952) announced a financing plan through the placement of existing shares and subscription for new shares, raising approximately HKD 1.57 billion, netting about HKD 1.55 billion after expenses [1][2] - The placement involves issuing 22,561,000 shares at a price of HKD 69.70 per share, representing a discount of approximately 10.1% to the last closing price of HKD 77.55 and a 5.0% discount to the average closing price of HKD 73.35 over the preceding five trading days [1] - The number of shares being placed corresponds to about 6.87% of the total issued shares as of the announcement date, and approximately 6.43% of the total issued shares after the completion of the subscription [1] Group 2 - The funds raised will be allocated as follows: approximately HKD 780 million for global research and development of pipeline products, around HKD 620 million for commercialization efforts, and about HKD 160 million for general operational and administrative expenses [2] - The issuance is conducted under a general mandate granted by the shareholders, with the subscription expected to complete on the second business day after the last condition is met, but no later than 10 days after the placement and subscription agreement date [2]
云顶新耀 ：通过一般授权配售及认购股份募资约 15.7 亿港元 药物研发及商业化推进